Avastin 100 MG 4 ML

Avastin is a vascular endothelial growth factor–specific angiogenesis inhibitor indicated for the treatment of:

1. Metastatic colorectal cancer,withintravenous5–fluorouracil–based

• chemotherapy for first– or second–line treatment.

2. Non–squamous non–small cell lung cancer,with carboplatin and paclitaxel

• for first line treatment of un-resectable, locally advanced, recurrent or
• metastatic disease.

3. Metastatic breast cancer,with paclitaxel for treatment of patients who have:

• not received chemotherapy for metastatic HER2–negative breast cancer.

–  Effectiveness based on improvement in progression–free survival. No data available demonstrating improvement in disease–related symptoms or survival with Avastin.
–  Not indicated for disease progression following anthracycline and taxane chemotherapy administered for metastatic disease.

4. Glioblastoma, as a single agent for adult patients with progressive disease following prior therapy.
– Effectiveness based on improvement in objective response rate. No data available demonstrating improvement in disease–related symptoms or survival with Avastin.

5. Metastatic renal cell carcinoma with interferon alfa.

Side-effects/Adverse Reactions:

Most common adverse reactions incidence (>10% and at least twice the control arm rate) are epistaxis, headache, hypertension, rhinitis, proteinuria, taste alteration, dry skin, rectal hemorrhage, lacrimation disorder, back pain and exfoliative dermatitis.

Manufactured by Roche